Aequus Announces Change to Proposed $300,000 Equity Financing

Aequus Pharmaceuticals (TSXV:AQS) a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, is pleased to announce that, further to its news release dated January 11, 2018 announcing a proposed $300,000 equity financing, it now intends to complete the equity financing of 1,000,000 units of the Company at a price of $0.30 per Unit.
As quoted in the press release:

Each Warrant shall entitle the holder thereof to purchase one common share at an exercise price of $0.50 for a period of twenty-four months following the Closing Date. The Warrants will include an acceleration provision, exercisable at the Company’s option, if the Company’s daily volume weighted average share price is greater than $0.85 for 10 consecutive trading days.

Click here to read the full press release.